

Efficacy and safety of Kangfuxin liquid combined with aminosalicylic acid for the treatment of ulcerative colitis

A systematic review and meta-analysis

Hui-biao Li, MM^a, Mu-yuan Chen, MM^a, Zhen-wen Qiu, PhD^a, Qing-qun Cai, MM^a, De-tang Li, MM^a, Hong-mei Tang, PhD^{a,*}, Xin-lin Chen, PhD^{b,*}

Abstract

Background: To systematically evaluate the clinical efficacy and safety of Kangfuxin liquid (KFXL) combined with aminosalicylic acid (ASA) in treating ulcerative colitis (UC).

Methods: The PubMed, Cochrane Library, Embase, CBM, Wan fang, the Chinese Scientific Journal Database (VIP), and Chinese National Knowledge Infrastructure (CNKI) databases were systematically searched for randomized controlled trials of KFXL combined with ASA for UC from the inception dates to March 3, 2017. Two researchers independently screened the literature, extracted data, and evaluated the methodological quality according to the inclusion criteria. The meta-analysis was performed using Review Manager software (RevMan, Version 5.3, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014), and the risk of bias was assessed using the Cochrane Collaboration Tool.

Results: A total of 39 randomized controlled trials (RCTs) involving 3204 patients fulfilled the inclusion criteria. Compared with ASA alone, KFXL combined with ASA significantly improved the clinical effectiveness rate [RR = 1.19, 95% CI: (1.16, 1.23), P < .00001], reduced the relapse rate [RR = 0.26, 95% CI: (0.18, 0.38), P < .00001], reduced the inflammation factor levels of TNF-a, IL-1, IL-6, IL-8, and C-reactive protein, reduced the coagulation index of fibrinogen, increased the coagulation index of prothrombin time, and mean platelet volume, and reduced the clinical symptoms of abdominal pain, diarrhoea, pus and bloody stool, and tenesmus. However, KFXL combined with ASA did not increase the adverse event incidence [RR = 0.74, 95% CI (0.42, 1.32), P = .31], and no severe adverse events were reported.

Conclusion: KFXL combined with ASA has good therapeutic effect for UC and might be a safe approach in managing UC. More high-quality, multicenter randomized, double-blind trials with a large sample size are required to generate a high level of clinical evidence.

Abbreviations: 5-ASA = mesalazine, ASA = aminosalicylic acid, bid = bis in die, CI = confidence interval, CRP = C-reactive protein, en = enema, FIB = fibrinogen, KFXL = Kangfuxin liquid; , MPV = mean platelet volume, OSLS = olsalazine sodium, Plt = platelet, po = peros, PT = prothrombin time, qd = quaque die, qid = quater in die, qn = quaque nocte, RR = risk ratio, SASP = sulfasalazine, SMD = standardized mean difference, tid = ter in die, UC = ulcerative colitis.

Keywords: aminosalicylic acid, Kangfuxin liquid, meta-analysis, ulcerative colitis

Editor: Somchai Amornyotin.

Consent for publication: All the authors declare that they agree to publish the paper in "Medicine."

The authors have no conflicts of interest to disclose.

Supplemental Digital Content is available for this article.

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc.

Medicine (2018) 97:21(e10807)

Received: 30 August 2017 / Accepted: 27 April 2018 http://dx.doi.org/10.1097/MD.0000000000010807

HBL and MYC equally contributed to this study.

Ethics approval and consent to participate: All analyses were based on previously published studies; thus, no ethical approval or patient consent was required.

Availability of data and materials: All data supporting the findings in this study are included within the manuscript and the two appendix files, http://links.lww.com/MD/ C246.

Funding: This study was supported by the National Natural Science Foundation of China (No.: 81403296,81774451), the Outstanding Youth Foundation of Guangdong Province Colleges and Universities (No: YQ2015041), the Young Talents Foundation of Guangzhou University of Chinese Medicine (No: QNYC20140101), the Natural Science Foundation of Guangdong Province (No: 2017A030313827), Administration of Traditional Chinese Medicine of Guangdong Province (No: 20182033), the Chuang Xin Qiang Yuan programme of First Affiliated Hospital of Guangzhou University of Chinese Medicine (No.: 2017QN02), and Guangdong high level universities programme of Guangzhou University of Chinese Medicine.

^a The First Clinical College, The First Affiliated Hospital, ^b School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.

^{*} Correspondence: Xin-lin Chen, School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangdong, China (e-mail: chenxlsums@126.com), Hong-mei Tang, The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangdong, China (e-mail: tanghongmei2000@163.com).

This is an open access article distributed under the Creative Commons Attribution-ShareAlike License 4.0, which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms.

1. Introduction

Ulcerative colitis (UC) is a chronic nonspecific inflammatory disease caused by immune abnormalities, mental disorders, genetics, and other factors. Its main clinical manifestations are abdominal pain, diarrhoea, bloody stool, weight loss, etc.^[1] According to an epidemiological survey, the highest incidence rates of UC in Europe, Asia, and North America were 24.3/10 million, 6.3/10 million, and 19.2/10 million, respectively, and the highest prevalence rates were 505/10 million, 63.6/10 million, and 249/10 million, respectively.^[2] The incidence rates of UC in Asia, Latin America, South Africa and other developing countries and regions are increasing year by year. UC has become one of the most common diseases in the world.^[3,4] UC seriously affects human health and quality of life because of its long duration and recurrent attacks, and it has the risk of developing into colorectal cancer.^[5]

In recent years, a large number of clinical studies have shown that KFXL combined with ASA has a good effect in the treatment of UC. KFXL is a Chinese medicine extracted from *Periplaneta americana* dried worms. The main components of the drug are polyhydric alcohols, peptides, mucin, amino acids and other active substances, with the functions of acid suppression, antiinflammation, improvement of gastrointestinal mucosal microcirculation, promotion of granulation tissue hyperplasia, acceleration of diseased tissue regeneration, and improvement of immunity.^[6,7] Pharmacological studies have found that KFXL can inhibit the expression of MMP-3 and MMP-13, decrease the levels of NF- κ B, IL-1 β , TNF- α , and INF- γ , increase the level of IL-4, and upregulate the expression of EGF and HGF in colonic mucosa to achieve the purpose of treating UC.^[8–12]

However, no meta-analysis has been conducted to summarize these research studies to determine whether KFXL combined with ASA is more efficacious than ASA alone in the treatment of UC. To provide more evidence for clinical decision making, we collected published studies covering RCTs of KFXL combined with ASA vs ASA alone in the treatment of UC and conducted a meta-analysis to assess its efficacy and safety.

2. Methods

2.1. Information sources and search strategies

A computerized search of the PubMed, Embase, Medline, Cochrane Library, the Chinese National Knowledge Infrastructure (CNKI), the Chinese Scientific Journal Database (VIP), the Chinese Biomedical Literature Database (CBM), and the Wanfang databases were conducted from inception to March 3, 2017. There was no restriction on language or publication status. The search terms for literature searching were as follows: "Kangfuxin," "Kangfuxin liquid," or "Kangfuxin Ye"; "ulcerative colitis"; and "randomized controlled trial," "controlled clinical trial," "random," "randomly," "randomized" or "control." To collect sufficient trials, the reference lists of retrieved articles were also reviewed.

2.2. Inclusion criteria

We conducted this study according to the preferred reporting items for systematic reviews and meta-analysis (PRISMA statement).^[13]

Studies were included for analysis if they satisfied the following criteria. *Participants*: all participants enrolled in this study were diagnosed as UC.^[14–20] No limitations on gender, age, or ethnicity of the participants were set. *Type of design:* RCTs were included, regardless of blinding. Animal studies were not

considered. *Type of intervention*: KFXL combined with ASA was chosen for the treatment group and ASA for the control group. The ASA used in the treatment groups should be the same as the controls in the category, dosage and method of administration. If other co-interventions such as another herbal formula, cupping, Tai Chi, moxibustion, acupuncture, qigong, massage, yoga, and aromatherapy were used in either the treatment group or the control group, those studies were excluded. *Type of outcome:* outcomes included at least the total clinical effectiveness rate or other indices of clinical improvement. When several trials from the same authors were identified as duplicates, we only included the most recent trial with the largest number of patients or longer follow-up. There were no language or publication status restrictions.

2.3. Data extraction

Two of the 3 investigators (HL, MC or DL) independently screened all the titles and abstracts of the eligible studies. The following information from primary trials was extracted: first author name, year of publication, age, gender, number of patients, details of interventions, co-interventions, outcomes, the duration of treatment, and adverse effects. Disagreements were resolved through discussion or from a third partner.

2.4. Assessment of risk of bias

Two reviewers (HL, MC) independently evaluated the risk of bias of each study using the assessment tool from the Cochrane Handbook.^[21] The criteria consisted of the following 7 items: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessments, incomplete outcome data, selective reporting, and other sources of bias. A judgement of "low" indicated low risk of bias, "high" indicated high risk of bias, and "Unclear" indicated unclear risk of bias. The disagreements in data collection were discussed with a third author (DL) and resolved by a consensus process.

2.5. Data analysis

The meta-analysis was performed using the Review Manager 5.3 software. Risk ratio (RR) and 95% confidence interval (CI) were calculated for dichotomous data. For continuous data, standardized mean difference (SMD) and 95% CI were calculated. If different measurement indices that adopted different tools were used in the various studies, SMD was preferred over the weighted mean difference. The heterogeneity among the trials was identified by χ^2 , using Cochrane Handbook Q test and quantified by I^2 , which determines the per cent of the total variability that cannot be ascribed to chance. A fixed-effects model was used when there was no significant heterogeneity $(P > .05, I^2 < 50\%)$. Otherwise, a random-effects model was applied (P < .05, $I^2 > 50\%$). Subgroup analyses were carried out based on the doses and medicines. Publication bias was assessed by funnel plot analysis if the group included more than 10 trials. When possible, sensitivity analyses were conducted for all outcomes.

3. Results

3.1. Study identification

A total of 823 potentially relevant articles were initially screened in the 7 electronic databases based on our literature search strategy. After removing 544 duplicates, 279 articles were



identified for further analysis. The titles and abstracts of the remaining articles were read by the reviewers, and 92 articles that did not meet the inclusion criteria were excluded. Next, 104 articles were checked for the full texts, and 65 articles were excluded. Finally, 39 trials were included for further appraisal and data extraction.^[22–60] A flowchart shows the process of study selection and identification (Fig. 1).

3.2. Study characteristics

All the eligible trials were based on randomized controlled trials. A total of 3204 UC patients were enrolled, with 1622 in the treatment group and 1582 in the control group. The included trials were published as the full text from 2006 to 2017. All of these trials were carried out in China, and all the participants involved were Chinese. The number of patients in the intervention group varied from 36 to 268. The duration of the treatment ranged from 14 days to 60 days. All the studies used a two-arm design (one treatment group vs one control group). For interventions, patients in the control group received ASA, including 5-ASA (n=28),^[22–49] SASP (n=10),^[50–59] and OSLS (n=1).^[60] Patients in the treatment groups were treated with KFXL on the basis of the control group. The basic characteristics of the 39 included randomized trials are summarized in Table 1.

3.3. Risk of bias

All the trials mentioned random allocation. Only 11 trials^[22–24,27,34,41,42,46,51,53,54] described the method of randomization (random number table), and 2 trials^[30,56] were randomized according to the order of visits, which means a high risk of bias; the other trials did not mention any information about randomization methods. All the trials did not state the method

of allocation concealment and blinding. Incomplete outcome data, selective outcome reporting, and other sources of bias were assessed as unclear risk of bias in all of the trials. The risk of bias in all the trials was considered to have a "high risk of bias." The details of the risk of bias of each trial are presented in Figures 2 and 3.

3.4. Clinical remission rate

Thirty-nine studies^[22–60] in UC patients were compared with respect to the primary outcome of clinical remission. There was no significant heterogeneity for the clinical remission rate between the 2 groups (P=.31, $I^2=9\%$). The meta-analysis was performed using a fixed-effects model. The results showed that the clinical remission of KFXL combined with ASA treatment improved significantly compared with ASA treatment (P < .00001), with a RR of 1.19 and 95% CI (1.16, 1.23).

3.5. Subgroup analysis of different medicines

Subgroup analysis was used to evaluate the efficacy of different medicines. Compared with ASA alone, KFXL plus SASP, and KFXL plus 5-ASA both had significant improvements in clinical remission, with RR=1.17 (95% CI=1.11, 1.23, n=10), and RR=1.20 (95% CI=1.16, 1.24, n=28), respectively (Fig. 4). This finding indicates that KFXL combined with ASA may have better potential clinical efficacy than ASA used alone.

3.6. Subgroup analysis of different doses

Subgroup analysis was used to evaluate the efficacy of different doses. Compared with ASA alone, doses of 30 mL (en, qd/qn), 50 mL (en, qd/qn), 50 mL (en, bid), 100 mL (en, qd), and 10 mL (po, tid) of KFXL combined with ASA all had significant improvements in clinical remission, with RR=1.14 (95% CI=1.07, 1.22, n=6), RR=1.18 (95% CI=1.13, 1.24, n=15), RR=1.17 (95% CI=1.10, 1.25, n=4), RR=1.24 (95% CI=1.14, 1.34, n=7), and RR=1.23 (95% CI=1.10, 1.39, n=3), respectively (Fig. 5).

3.7. Improvement of Intestinal mucosa

Five trials^[35,38,46,52,56] compared the improvement of intestinal mucosa. There was statistical heterogeneity between the 2 groups (P=.02, $I^2=65\%$), so the random-effects model was used. The pooled analysis revealed that the improvement of intestinal mucosa between the treatments was significantly different (RR = 1.37, 95% CI=1.17, 1.61, P=.0001) (Fig. 6).

3.8. Reduction rate of UC symptoms

Five trials^[30,33,47,55,59] reported the reduction rate of UC symptoms. The meta-analysis results showed that in both the treatment and control group, there was a significant decrease in symptoms of abdominal pain, diarrhoea, bloody stool and tenesmus and that the reduction of UC symptoms in the control group was smaller than that in the treatment group (Fig. 7).

3.9. Abdominal pain

Five trials^[30,33,47,55,59] compared the abdominal pain between the 2 drug treatments. There was no significant heterogeneity between the 2 groups (P=.37, $I^2=6\%$), so the fixed-effects model was used. The pooled analysis suggested that the difference between the 2 groups was statistically significant (RR=0.39, 95% CI=0.28, 0.53, P<.00001) (Fig. 7).

Table 1

The characteristic of the eligible trials.

		Intervention measures			
Trials	Sample size	Treatment group	Control group	Treatment time, days	Outcomes
Huang et al ^[22]	40/40	5-ASA (po,1g,tid)+ KFXL(en,30mL,qd)	5-ASA(po,1g,tid)	30	CE, CI, IFL, RR, AE
Tang et al ^[23]	30/30	5-ASA(po,1g,tid)+ KFXL(en,30 mL,qd)	5-ASA(po,1g,tid)	28	CE, CI, IFL, RR
Shi et al ^[24]	57/57	5-ASA(po,1g,tid)+ KFXL(en,30 mL,qd)	5-ASA(po,1g,tid)	30	CE, IFL, RR, AE
Li et al ^[25]	36/36	5-ASA(po,1g,tid)+ KFXL(en,50 mL,qn)	5-ASA(po,1g,tid)	30	CE, IFL, RR, AE, TLSL
Liu et al ^[26]	30/30	5-ASA(po,1g,qid)+ KFXL(en,100 mL,qd)	5-ASA(po,1g,qid)	60	CE
Pan et al ^[27]	50/50	5-ASA(po,1g,tid)+ KFXL(en,50 mL,qn)	5-ASA(po,1g,tid)	56	CE
Wang ^[28]	32/32	5-ASA(po,1g,tid)+ KFXL(en,50 mL,qd)	5-ASA(po,1g,tid)	28	CE
Jin et al ^[29]	90/90	5-ASA(po,1.5g,qd)+ KFXL(en,50 mL,qd)	5-ASA(po,1.5g~4g,qd)	30	CE, IFL, QLS
He ^[30]	70/70	5-ASA(en,4g,qn)+ KFXL(en,50 mL,qn)	5-ASA(en,4g,qn)	28	CE, SP
Bai et al ^[31]	38/30	5-ASA(po,1g,qid)+ KFXL(po,10 mL,tid)	5-ASA(po,1g,qid)	28	CE, RR
Zhang ^[32]	28/28	5-ASA(po,1g,tid)+ KFXL(en,50 mL,qn)	5-ASA(po,1g,tid)	14	CE
Zheng et al ^[33]	47/32	5-ASA(po,1g,tid)+ KFXL(en,100 mL,bid)	5-ASA(po,1g,tid)	28	CE, SP
Gong et al ^[34]	40/40	5-ASA(po,1g,tid)+ KFXL(en,50 mL,qd)	5-ASA(po,1g,tid)	28	CE, CI, RR, AE
Ouyang and Zhang ^[35]	42/42	5-ASA(po,1g,tid)+ KFXL(en,50 mL,qn)	5-ASA(po,1g,tid)	28	CE, IM
Ouyang and Yan ^[36]	34/33	5-ASA(po,1g,qid)+ KFXL(en,30 mL,qn)	5-ASA(po,1g,qid)	30	CE, IFL, AE
Li et al ^[37]	41/42	5-ASA(po,1g,tid)+ KFXL(en,30 mL,qn)	5-ASA(po,1g,tid)	30	CE, IFL, AE
Tan et al ^[38]	35/35	5-ASA(po,1g,tid)+ KFXL(en,30 mL,qn)	5-ASA(po,1g,tid)	28	CE, IM
Zeng ^[39]	20/20	5-ASA(po,1g,tid)+ KFXL(en,50 mL,qn)	5-ASA(po,1g,tid)	28	CE
Ma ^[40]	30/30	5-ASA(po,1g,tid)+ KFXL(en,100 mL,qn)	5-ASA(po,1g,tid)	28	CE, RR, AE
Fei ^[41]	50/48	5-ASA(po,1g,qid)+ KFXL(en,50 mL,qd)	5-ASA(po,1g,qid)	28	CE
Pi ^[42]	18/18	5-ASA(po)+ KFXL(en,50 mL,bid)	5-ASA(po)	40	CE
Liu et al ^[43]	32/32	5-ASA(po,1g,qid)+ KFXL(en,50 mL,qn)	5-ASA(po,1g,qid)	28	CE, IFL
Gen et al ^[44]	40/40	5-ASA(po,1g,qid)+ KFXL(en,100 mL,qd;po,10 mL,tid)	5-ASA(po,1g,qid)	56	CE
Zhang ^[45]	60/60	5-ASA(po,1g,qid)+ KFXL(en,qd)	5-ASA(po,1g,qid)	56	CE, IFL
Jiao ^[46]	51/51	5-ASA(po,1g,qid)+ KFXL(en,100 mL,qd)	5-ASA(po,1g,qid)	60	CE, IM
Zheng and Li ^[47]	30/30	5-ASA(po,1g,tid)+ KFXL(en,50 mL,bid)	5-ASA(po,1g,tid)	14	CE, SP
Xu ^[48]	20/20	5-ASA(po,1g,qid)+ KFXL(en,50 mL,qn)	5-ASA(po,1g,qid)	2 courses	CE
Yin ^[49]	27/27	5-ASA(po,1g,tid)+ KFXL(en,50 mL,qn)	5-ASA(po,1g,tid)	28	CE, SP, RR
Wang ^[50]	30/30	SASP(po,1g,qid)+ KFXL(en,100 mL,qd)	SASP(po,1g,qid)	35	CE
Wang et al ^[51]	26/18	SASP(po,1.5g,tid)+KFXL(en,50 mL,qn)	SASP(po, 1.5g, tid)	40	CE
Xu ^[52]	30/30	SASP(en,2g,bid)+ KFXL(en,30 mL,bid)	SASP(en,2g,bid)	14	CE, IM
Wu and Yu ^[53]	35/20	SASP(po,1.5g,qid)+KFXL(en,100 mL,qn)	SASP(po,1.5g,qid)	42	CE
Li ^[54]	44/43	SASP(po,1g,qid)+ KFXL(en,50 mL,bid)	SASP(po,1g,qid)	56	CE
Fan et al ^[55]	52/52	SASP(po,1g,qid)+ KFXL(en,100 mL,qd)	SASP(po,1g,qid)	28	CE, SP
Yan et al ^[56]	41/47	SASP(en,4g,qd)+ KFXL(en,50 mL,qd)	SASP(en,4g,qd)	28	CE, IM, AE
Liu ^[57]	30/30	SASP(po,50–75 mg/kg/d)+ KFXL(po,10 mL,tid)	SASP(po,50–75 mg/kg/d)	56	CE, RR
Liu ^[58]	42/45	SASP(po,1g,qid)+ KFXL(en,100 mL,qd)	SASP(po,1g,qid)	35	CE
Gou ^[59]	134/134	SASP(po,1g,qid)+ KFXL(en,50 mL,bid)	SASP(po,1g,qid)	40	CE, SP, AE
Jin ^[60]	40/40	OSLS(po,0.5g,Tid)+ KFXL(po,10 mL,tid)	OSLS(po,0.5g,tid)	15	CE

5-ASA = Mesalazine, AE = adverse effects, bid = bis in die, CE = clinical efficacy, CI = coagulation index, en = enema, IFL = inflammation factor Level, IM = intestinal mucosa, KFXL = Kangfuxin liquid, OSLS = olsalazine sodium, Po = peros, qd = quaque die, qid = quater in die, QLS = quality of life score, qn = quaque nocte, RR = relapse rate, SASP = Sulfasalazine, SP = symptoms, tid = ter in die, TLSL = T lymphocyte subsets level.

3.10. Diarrhoea

Five trials^[30,33,47,55,59] compared the diarrhoea between the 2 drug treatments. There was no significant heterogeneity between the 2 groups (P=.33, I^2 =14%), so the fixed-effects model was used. The pooled analysis suggested that the difference between the 2 groups was statistically significant (RR=0.44, 95% CI=0.31, 0.61 P<.00001) (Fig. 7).

3.11. Bloody Stool

Five trials^[30,33,47,55,59] compared bloody stool between the 2 drug treatments. There was no significant heterogeneity between the 2 groups (P=.32, I^2 =15%), so the fixed-effects model was used. The pooled analysis suggested that the difference between the 2 groups was statistically significant (RR=0.44, 95% CI= 0.29, 0.66, P<.0001) (Fig. 7).

3.12. Tenesmus

Three trials^[30,33,59] compared the tenesmus between the 2 drug treatments. There was no significant heterogeneity between the 2 groups (P=.89, $I^2=0\%$), so the fixed-effects model was used.





	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other blas
Bai BJ2012	?	?	?	?	?	?	?
Fan GX2014	?	?	?	?	?	?	?
Fei FM2014	•	?	?	?	?	?	?
Gen H2016	?	?	?	?	?	?	?
Gong JQ2015	•	?	?	?	?	?	?
Gou CH2010	?	?	?	?	?	?	?
He DL2015	•	?	?	?	?	?	?
Huang DX2013	•	?	?	?	?	?	?
Jiao JH2016	•	?	?	?	?	?	?
Jin JR2015	?	?	?	?	?	?	?
Jin P2013	?	?	?	?	?	?	?
LI CM2014	•	?	?	?	?	?	?
Liu HY2014	?	?	?	?	?	?	?
Liu J2013	?	?	?	?	?	?	?
Liu LY2014	?	?	?	?	?	?	?
Liu YJ2015	?	?	?	?	?	?	?
Li Y2012	?	?	?	?	?	?	?
LIY2017	?	?	?	?	?	?	?
Ma J2014	?	?	?	?	?	?	?
Ouyang WG2014	?	?	?	?	?	?	?
Ouyang YJ2011	?	3	?	3	?	3	3
Pan G2011		1	1	2	1	1	2
Pi J2011	-	?	?	?	1	?	2
Shi ZJ2016	-	0	1	0	0	0	0
Tang QF2016		1	1	*	0	0	
Tan 22014		0	1	0	0	0	0
Wang JM2006		2		2	0	0	2
Wang L2012	0	0	•	1	0	0	2
wang GL2014		2	1	2	2	0	2
VU 052015	2	2	2	2	2	2	2
XII CF 2015	2	2	2	2	2	2	2
Xu N2U14	-	2		•			2
Vin CODOC 1	-	2	•	2	•	•	2
7epg 000014	2	2	2	2	2	2	2
Zeng QG2013	2	2	2	2	2	2	2
Zhang C2012	2	2	2	2	2	2	2
Zhang 02016	2	2	2	2	2	2	2
Zheng Co2015	2	2	2	2	2	2	2
2000g F2013	-	•	•	•	•	-	-

Figure 3. Risk of bias summary.

The pooled analysis suggested that the difference between the 2 groups was statistically significant (RR=0.08, 95% CI=0.02, 0.41, P=.002) (Fig. 7).

3.13. Reduction of Inflammation factor Level

The inflammation factor level was evaluated in 9 trials.^[22–25,29,36,37,43,45] The number of trial participants ranged from 60

Study or Subaroup	Events	Total	Events	Total	Weight	M-H. Fixed, 95% CI	M-H, Fixed, 95% Cl
1.1.1 KFXL combined	with SASP	- ordi	- terns	rout!	- Autoped	the state of the s	
an GY2014	48	52	40	52	3 2%	1 20 11 01 1 421	
Cou CH2010	120	124	112	124	0.0%	1 15 11 06 1 251	
LCM201A	42	44	26	42	2.0%	1 17 11 00 1 27	
hu 12012	20	42	33	45	2.0%	1 10 10 02 1 201	
Ju J2013	30	92	31	40	1.70	1.10 [0.93, 1.30]	
JULT2014	20	30	21	30	1.770	1.33 [1.04, 1.72]	
Vang JM2006	24	20	15	18	1,4%	1.11 [0.88, 1.40]	
Nang L2012	28	30	23	30	1.8%	1.22 [0.98, 1.52]	
WU W2009	33	35	17	20	1.7%	1.11 [0.91, 1.30]	
CU CF2015	28	30	21	30	1.7%	1.33 [1.04, 1.72]	
ran AH2013	39	41	42	47	3.1%	1.06 [0.94, 1.20]	
subtotal (95% CI)	12.000	404	1.000	449	29.1%	1.17[1.11, 1.23]	· · · ·
Fotal events	437		363				
Heterogeneity: Chi [#] = Fest for overall effect:	5.54, df = 9 (Z = 5.94 (P <	P = 0.78) 0.00001	(1 [#] = 0%)				
1.1.2 KFXL combined	with 5-ASA						
Bai BJ2012	37	38	28	30	2.5%	1.04 [0.94, 1.16]	
ei FM2014	48	50	37	48	3.0%	1.25 [1.06, 1.47]	
3en H2016	38	40	31	40	2.5%	1.23 [1.02, 1.47]	
3ong JQ2015	38	40	30	40	2.4%	1.27 [1.04, 1.54]	
He DL2015	66	70	52	70	4.1%	1.27 11.09, 1.471	
Juang DX2013	39	40	35	40	2.8%	1 11 10 98 1 271	
lian .IH2016	46	51	33	51	2.6%	1 39 11 12 1 741	
lin IR2015	83	90	73	90	5.9%	1 14 11 01 1 291	
122012	40	41	27	42	2.0%	1 11 10 00 1 251	
12012	22	26	27	26	2.010	1 22 10 00 1 611	
in LIV2014	25	30	20	30	2.170	1 10 11 00 1 421	
Ju H12014	31	32	20	32	4.500	1.19 [1.00, 1.42]	
10 102010	20	20	22	30	1.0%	1 26 11 02 1 661	
1a J2014	29	30	23	30	1.8%	1.20 [1.02, 1.55]	
Juyang WG2014	34	34	32	33	2.0%	1.03 [0.95, 1.12]	
Juyang YJ2011	38	42	32	42	2.5%	1.19 [0.98, 1.44]	
an G2011	47	50	39	50	3.1%	1.21 [1.02, 1.42]	
1J2011	18	18	17	18	1.4%	1.06 [0.91, 1.23]	
Shi ZJ2016	54	57	46	57	3.7%	1.17 [1.02, 1.35]	
Fan Z2014	30	35	25	35	2.0%	1.20 [0.94, 1.54]	
Tang QF2016	28	30	22	30	1.7%	1.27 [1.01, 1.61]	
Wang QL2014	31	32	27	32	2.1%	1.15 [0.98, 1.35]	
0u N2014	17	20	16	20	1.3%	1.06 [0.80, 1.41]	
rin CG2014	25	27	20	27	1.6%	1.25 [0.98, 1.60]	
Ceng QG2013	18	20	15	20	1.2%	1.20 [0.90, 1.61]	
hang C2012	27	28	25	28	2.0%	1.08 [0.93, 1.25]	
chang D2016	54	60	43	60	3.4%	1.26 [1.05, 1.50]	
Cheng LJ2015	45	47	25	32	2.4%	1.23 [1.01, 1.49]	
Cheng P2013	30	30	22	30	1.8%	1.36 [1.09, 1.69]	
Subtotal (95% CI)		1118		1093	68.8%	1.20 [1.16, 1.24]	•
fotal events	1051		857				
Heterogeneity: Chi [#] = Test for overall effect.	34.34, df = 2 Z = 10.30 (P	7 (P = 0.1 < 0.0000	16); I [#] = 21 11)	%			
.1.3 KFXL combined	with Olsala	tine					
Jin P2013	36	40	26	40	2.1%	1.38 [1.08, 1.78]	
Subtotal (95% CI)		40		40	2.1%	1.38 [1.08, 1.78]	
Total events	36		26				
Heterogeneity: Not ap Test for overall effect:	plicable Z = 2.55 (P =	0.01)					
fotal (95% CI)		1622		1582	100.0%	1.19 [1.16, 1.23]	•
fotal events	1524		1246				120 - 120 - Carlos -
Heterogeneity: Chi#=	41.67, df = 3	8 (P = 0.3	31); P= 99	6			
		-	6.00				10 17 1 15

Figure 4. Meta-analysis of the clinical remission rate for the subgroup analysis of different medicines.

to 180. The meta-analysis results showed that the treatment groups were superior to the control groups in reducing the TNF- α , IL-1, IL-6, IL-8, and CRP levels.

3.14. Reduction of TNF- α

Nine trials^[22–25,29,36,37,43,45] evaluated the effect of TNF- α reduction. There was statistical heterogeneity between the 2 groups (P < .00001, I²=96%), so the random-effects model was used. The pooled analysis suggested that the difference between the 2 groups was statistically significant (P < .00001; SMD=-2.90; 95% CI [-3.93, -1.87]) (Fig. 8).

3.15. Reduction of IL-1

Five trials^[22,23,29,36,37] evaluated the effect of IL-1 reduction. There was statistical heterogeneity between the 2 groups (P=.01, I^2 =68%), so the random-effects model was used. The pooled analysis suggested that the difference between the 2 groups was statistically significant (P<.00001; SMD=-1.30; 95% CI [-1.67, -0.93]) (Fig. 9).

3.16. Reduction of IL-6

Five trials^[22,23,25,43,45] evaluated the effect of IL-6 reduction. There was statistical heterogeneity between the 2 groups (P < .00001, $I^2 = 94\%$), so the random-effects model was used. The pooled analysis suggested that the difference between the 2 groups was statistically significant (P < .00001; SMD = -2.57; 95% CI [-3.66, -1.48]) (Fig. 10).

	treatment	group	control (group		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
1.2.1 KFXL:30ml(en,q	d/qn)						a
Huang DX2013	39	40	35	40	2.8%	1.11 [0.98, 1.27]	
Li Y2012	40	41	37	42	2.9%	1.11 [0.98, 1.25]	
Ouyang WG2014	34	34	32	33	2.6%	1.03 [0.95, 1.12]	
Shi ZJ2016	54	57	46	57	3.7%	1.17 [1.02, 1.35]	
Tan Z2014	30	35	25	35	2.0%	1.20 [0.94, 1.54]	
Tang QF2016	28	30	22	30	1.7%	1.27 [1.01, 1.61]	
Subtotal (95% CI)		237		237	15.7%	1.14 [1.07, 1.22]	•
Total events	225		197				
Heterogeneity: Chi ² =	7.33, df = 5 (P = 0.20); = 32%				
Test for overall effect.	Z = 4.06 (P <	0.0001)				
1 2 2 KEVI ·50ml/on a	d(m)						
T.Z.Z RFAL.SUIII(EI),Q	40	50	27	40	2.00	4 35 14 00 4 471	
Comm 102014	40	10	20	40	3.0%	1.23 [1.00, 1.47]	
Gong JG2015	38	40	30	40	2.4%	1.27 [1.04, 1.34]	
He DL2015	60	10	52	70	4.1%	1.27 [1.09, 1.47]	
JIN JR2015	83	90	13	90	5.8%	1.14 [1.01, 1.28]	
LI Y2017	33	36	21	36	2.1%	1.22 [0.99, 1.51]	
Liu HY2014	31	32	26	32	2.1%	1.19 [1.00, 1.42]	
Ouyang YJ2011	38	42	32	42	2.5%	1.19 [0.98, 1.44]	
Pan G2011	47	50	39	50	3.1%	1.21 [1.02, 1.42]	
Wang JM2006	24	26	15	18	1.4%	1.11 [0.88, 1.40]	
Wang QL2014	31	32	27	32	2.1%	1.15 [0.98, 1.35]	
Xu N2014	17	20	16	20	1.3%	1.06 [0.80, 1.41]	
Yan AH2013	39	41	42	47	3.1%	1.06 [0.94, 1.20]	
Yin CG2014	25	27	20	27	1.6%	1.25 [0.98. 1.60]	
Zeng QG2013	18	20	15	20	1.2%	1,20 (0 90 1 61)	
Zhang C2012	27	29	25	28	2.0%	1 08 0 93 1 251	
Subtotal (95% Ch	21	604	20	600	37.8%	1.18 [1 13 1 24]	•
Total events	505	004	170	000	31.075	1.10[1.13, 1.24]	•
Hotorogon site Oh T	7 75 4 4	10 - 00	4/0				
Heterogeneity: Chi* = Test for overall effect	7.75, at = 14 7 = 7.06 (P <	(P = 0.9	0); I* = 0% 1)	2			
A SHARANA SHARAN							
1.2.3 KFXY:50ml(en,b	id)						
Gou CH2010	129	134	112	134	8.9%	1.15 [1.06, 1.25]	
Li CM2014	42	44	35	43	2.8%	1.17 [1.00, 1.37]	
Pi J2011	18	18	17	18	1.4%	1.06 [0.91, 1.23]	
Zheng P2013	30	30	22	30	1.8%	1.36 [1.09, 1.69]	
Subtotal (95% CI)		226		225	14.9%	1.17 [1.10, 1.25]	•
Total events	219		186				e la construcción de la construc
Heterogeneitr Chi2=	3 61 df= 3 (P=0.31	1- 12 = 17%	3			
Test for overall effect.	Z= 4.76 (P -	0.0000	1)				
1.2.4 KFXL:100ml(en,	qd)						
Fan GX2014	48	52	40	52	3.2%	1.20 [1.01, 1.42]	
Jiao JH2016	46	51	33	51	2.6%	1.39 [1.12, 1.74]	
Liu J2013	38	42	37	45	2.8%	1.10 [0.93, 1.30]	
Liu YJ2015	27	30	19	30	1.5%	1.42 [1.06, 1.91]	
Ma J2014	29	30	23	30	1.8%	1.26 [1.02, 1.55]	
Wang 2012	28	30	23	30	1.8%	1 22 10 98 1 521	
W/u W/2009	33	35	17	20	1.7%	1 11 0 91 1 361	
Subtotal (95% CI)	00	270		258	15.5%	1.24 [1.14 1.34]	•
Total events	249	2.0	102	200		in the second	
Heterogeneity Chiz-	5 08 df - 6 /	P=0.63) I2 = 0%				
Test for overall effect	Z = 5.23 (P =	0.0000	1)				
			(1)				
1.2.5 KFXL:10ml(po,ti	d)						
Bai BJ2012	37	38	28	30	2.5%	1.04 [0.94, 1.16]	
Jin P2013	36	40	26	40	2.1%	1.38 [1.08, 1.78]	
Liu LY2014	28	30	21	30	1,7%	1.33 [1.04. 1.72]	
Subtotal (95% CI)		108	1	100	6.2%	1.23 [1.10, 1.39]	•
Total events	101		75		Street,		the base of the
Heterogeneity Chiz=	10.33 df= 2	(P=0.0	06): IF = 8	1%			
Test for overall effect .	Z = 3.45 (P =	0.0006)				
1.2.6 The other doses	20	10	24	10	2 500	1 22 11 02 4 17	
Gen H2016	38	40	31	40	2.5%	1.23 [1.02, 1.47]	
Xu CF2015	28	30	21	30	1.7%	1.33 [1.04, 1.72]	
Zhang D2016	54	60	43	60	3.4%	1.26 [1.05, 1.50]	
Zheng LJ2015	45	47	25	32	2.4%	1.23 [1.01, 1.49]	
Subtotal (95% CI)		177		162	9.9%	1.25 [1.14, 1.39]	-
Total events	165		120				
Heterogeneity: Chi ² =	0.34, df = 3 (P = 0.95); I ² = 0%				
Test for overall effect.	Z= 4.47 (P -	0.0000	1)				
Total (95% Ch		1622		1600	100.0%	1 10 11 46 4 331	
Total evente	1524	1022	1246	1302	100.075	1.19 [1.10, 1.23]	
Hotorogeneity Chi2-	11 67 df - 3	9 /P - 0	31): 12-0	06			
Test for overall offect	7-1216/0	< 0 000	01)	~			0.5 0.7 1 1.5 2
Test for subgroup diff.	2 = 12.15 (P	- 1 22	df = 6 (D -	- 0 6 2)	2-0%		control group treatment group
Test for subdroup diffe	erences: Chi	= 4.23.	ul = 5 (P =	- 0.02).	= 0%		AATTIMA ATTACA TA

Figure 5. Meta-analysis of the clinical remission rate for the subgroup analysis of different doses.



3.17. Reduction of IL-8

Seven trials^[22,23,25,29,36,37,45] evaluated the effect of IL-8 reduction. There was statistical heterogeneity between the 2 groups (P < .00001, $I^2 = 84\%$), so the random-effects model was used. The pooled analysis suggested that the difference between the 2 groups was statistically significant (P < .00001; SMD=- 1.47; 95% CI [-1.91, -1.02]) (Fig. 11).

	treatment	group	control (roup		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fixe	ed, 95% Cl	
1.3.1 abdominal pain										
Fan GX2014	19	52	38	52	46.2%	0.50 [0.34, 0.74]				
Gou CH2010	2	60	6	58	7.4%	0.32 [0.07, 1.53]			-	
He DL2015	1	48	8	49	9.6%	0.13 [0.02, 0.98]		•	1	
Zheng LJ2015	1	41	6	27	8.8%	0.11 (0.01, 0.86)		-		
Zheng P2013	9	30	23	30	28.0%	0.39 10.22 0.701		_		
Subtotal (95% CI)		231		216	100.0%	0.39 [0.28, 0.53]		•	1	
Total events	32		81							
Heterogeneitr Chi ² =	4 26 df = 4	P = 0 37)· 12 = 6%							
Test for overall effect:	Z= 5.81 (P	< 0.0000	1)							
1.3.2 diarrhea								524		
Fan GX2014	16	52	35	52	48.4%	0.46 [0.29, 0.72]				
Gou CH2010	2	88	7	89	9.6%	0.29 [0.06, 1.35]			+	
He DL2015	1	63	6	60	8.5%	0.16 [0.02, 1.28]	-	•	+	
Zheng LJ2015	2	40	7	28	11.4%	0.20 [0.04, 0.89]	-			
Zhena P2013	11	30	16	30	22.1%	0.69 (0.39, 1.22)			+	
Subtotal (95% CI)		273		259	100.0%	0.44 [0.31, 0.61]		•		
Total events	32		71							
Heterogeneity: Chi ² = -	4.63. df = 4 (P = 0.33): = 14%							
Test for overall effect:	Z= 4.79 (P	< 0.0000	1)							
1.3.3 blood Stool										
Fan GX2014	14	52	24	52	44.2%	0.58 [0.34, 1.00]			1	
Gou CH2010	1	69	4	67	7.5%	0.24 [0.03, 2.12]	· · · · ·	•		
He DL2015	1	45	7	42	13.3%	0.13 [0.02, 1.04]			1	
Zheng LJ2015	1	40	6	29	12.8%	0.12 [0.02, 0.95]		•		
Zheng P2013	7	30	12	30	22.1%	0.58 [0.27, 1.28]			+	
Subtotal (95% CI)		236		220	100.0%	0.44 [0.29, 0.66]		•		
Total events	24		53							
Heterogeneity: Chi ² =	4.68. df = 4 ((P = 0.32)); ² = 15%							
Test for overall effect: 2	Z = 3.91 (P	< 0.0001))							
1.3.4 tenesmus										
Gou CH2010	0	54	3	55	19.7%	0.15 [0.01, 2.75]	-			
He DL2015	0	42	7	43	42.0%	0.07 [0.00, 1.16]	•	•	+	
Zheng LJ2015	0	34	5	21	38.3%	0.06 [0.00, 0.98]	+		1	
Subtotal (95% CI)		130		119	100.0%	0.08 [0.02, 0.41]	-			
Total events	0		15							
Heterogeneity: Chi2 = I	0.23, df = 2 ((P = 0.89); I= 0%							
Test for overall effect: 2	Z = 3.03 (P =	= 0.002)	ST SILNE							
							L.	1	1	
							0.01	0.1 control group	treatment group	100
Test for subaroup diffe	erences: Ch	= 4.22	df = 3 (P =	: 0.24).	I [*] = 29.09	6				
	Figu	ire 7.	Meta-ar	alysis	of UC	symptoms. UC=	=ulcerati	ve colitis.		

3.18. Reduction of CRP

Two trials^[29,45] evaluated the effect of CRP reduction. There was no significant heterogeneity between the 2 groups (P=.86, $I^2=$ 0%), so the fixed-effects model was used. The pooled analysis suggested that the difference between the 2 groups was statistically significant (P<.00001; SMD=-2.19; 95% CI [-2.47, -1.90]) (Fig. 12).

3.19. Effect on coagulation index

The effect on coagulation index was evaluated in 3 trials.^[22,23,34] The meta-analysis results showed that the experimental groups were superior to the control groups in reducing the FIB and platelet (Plt) values and in increasing the PT and MPV values.



Figure 8. Meta-analysis of the reduction of TNF-ain ulcerative of	colitis.
---	----------

	treat	treatment group Control group						Std. Mean Difference		Std. Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean SD Tota			Weight	IV, Random, 95% CI		为 CI			
Huang DX2013	0.52	0.18	40	0.82	0.22	40	19.4%	-1.48 [-1.98, -0.98]			•		
Jin JR2015	0.63	0.16	90	0.93	0.24	90	24.1%	-1.46 [-1.79, -1.13]			•		
LI Y2012	0.637	0.198	41	0.937	0.213	42	19.7%	-1.44 [-1.93, -0.96]			•		
Ouyang WG2014	0.612	0.178	34	0.935	0.221	33	17.9%	-1.59 [-2.15, -1.04]			•		
Tang QF2016	2.32	1.04	30	2.84	1.09	30	18.9%	-0.48 [-1.00, 0.03]			1		
Total (95% CI)			235			235	100.0%	-1.30 [-1.67, -0.93]					
Heterogeneity: Tau ² Test for overall effect	= 0.12; C Z = 6.90	hi ² = 12) (P < 0.)	53, df= 00001)	4 (P =	0.01); P	= 68%			-100	-50 control grou	0 p treat	50 ment group	100

	treatm	treatment group control group						Std. Mean Difference	Std. Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Rande	om, 95% Cl	
Huang DX2013	74.2	6.7	40	115.1	9.3	40	18.7%	-5.00 [-5.90, -4.09]				
LI Y2017	86.1	8.7	36	115.9	10.3	36	19.8%	-3.09 [-3.79, -2.40]			4	
Liu HY2014	12.25	3.24	32	16.74	3.62	32	20.4%	-1.29 [-1.83, -0.75]			•	
Tang QF2016	8.33	4.15	30	15.17	6.22	30	20.4%	-1.28 [-1.84, -0.72]			•	
Zhang D2016	93.6	17.1	60	138.6	19.9	60	20.7%	-2.41 [-2.88, -1.94]		1	1	
Total (95% CI)			198			198	100.0%	-2.57 [-3.66, -1.48]		1.1		
Heterogeneity: Tau ² =	= 1.44; Ch	1 ² = 64	.93, df=	= 4 (P «	0.0000	(1); I*=	94%		100	-50	0 50	100
Test for overall effect	Z= 4.62	(P < 0.)	00001)						-100	control group	treatment grou	up qu

	treat	nent gr	oup	conti	rol grou	p	1	Std. Mean Difference	Std. Mean Difference			ence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl		IV, Ra	ndom, 95	76 CI	
Huang DX2013	0.46	0.07	40	0.62	0.11	40	14.1%	-1.72 [-2.24, -1.20]			-		
Jin JR2015	0.43	0.17	90	0.65	0.29	90	16.0%	-0.92 [-1.23, -0.61]			1		
LI Y2012	0.41	0.05	36	0.64	0.1	36	12.5%	-2.88 [-3.55, -2.21]			-		
LI Y2017	0.478	0.062	41	0.698	0,201	42	14.4%	-1.46 [-1.94, -0.97]			-		
Ouyang WG2014	0.455	0.084	34	0.699	0.21	33	13.8%	-1.52 [-2.06, -0.97]					
Tang QF2016	87.51	43.18	30	122.83	87.45	30	14.1%	-0.62 [-1.13, -0.10]			1		
Zhang D2016	155.5	27.3	60	199.3	34.6	60	15.2%	-1.40 [-1.80, -1.00]			1		
Total (95% CI)			331			331	100.0%	-1.47 [-1.91, -1.02]					
Heterogeneity: Tau*:	= 0.30; C	hi ² = 37.	61, df=	6 (P < 0	00001)	1ª = 84	1%	And a second second	100	10	-	1	
Test for overall effect	Z= 6.47	(P < 0.1	00001)						-100	control gro	up treat	ment group	10

	treatn	nent gr	oup	cont	roi gro	up		Std. Mean Difference		Std. Mean D	ifference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fixed,	95% CI	
Jin JR2015	5.06	1.45	90	9.75	2.62	90	59.7%	-2.21 [-2.58, -1.83]				
Zhang D2016	2.1	0.9	60	4.4	1.2	60	40.3%	-2.15 [-2.61, -1.70]		1		
Total (95% CI)			150			150	100.0%	-2.19 [-2.47, -1.90]				
Heterogeneity: Chi#=	0.03, df	= 1 (P =	0.86);	12=0%					100	10	10	100

Figure 12. Meta-analysis of the reduction of CRP in ulcerative colitis. CRP = C-reactive protein.

	treatm	treatment group Control group					Std. Mean Difference			Std. Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Rande	m, 95% (C1		
Gong JQ2015	2.4	0.2	40	3.3	0.3	40	32.5%	-3.50 [-4.20, -2.79]						
Huang DX2013	2.54	0.14	40	2.96	0.25	40	33.7%	-2.05 [-2.60, -1.51]			•			
Tang QF2016	2.47	0.48	30	3.06	0.71	30	33.8%	-0.96 [-1.50, -0.42]		0	1			
Total (95% CI)			110			110	100.0%	-2.15 [-3.51, -0.80]						
Heterogeneity: Tau*:	= 1.34; CH	ni#= 31	53, df=	= 2 (P <	0.000	01); P=	94%		100	10	<u>!</u>	+		
Test for overall effect	Z= 3.11	(P = 0.	002)						-100	-50 Control group	treatme	nt group	10	

Figure 13. Meta-analysis of the reduction of FIB in ulcerative colitis. $\mathsf{FIB}\!=\!\mathsf{fibrinogen}.$

3.20. FIB

Three trials^[22,23,34] evaluated the effect of FIB reduction. There was statistical heterogeneity between the 2 groups (P < .00001, I^2 = 94%), so the random-effects model was used. The pooled analysis suggested that the difference between the 2 groups was statistically significant (P = .002; SMD = -2.15; 95% CI [-3.51, -0.80]) (Fig. 13).

3.21. Plt

Two trials^[23,34] evaluated the effect of Plt reduction. There was statistical heterogeneity between the 2 groups (P < .0001, $I^2 = 98\%$), so the random-effects model was used. The pooled analysis suggested that the difference between the 2 groups was not statistically significant (P = .47; SMD = 0.91; 95% CI [-1.54, 3.37]) (Fig. 14).

3.22. PT

Two trials^[23,34] evaluated the effect of PT increase. There was no significant heterogeneity between the 2 groups (P=.83, $I^2=0\%$), so the fixed-effects model was used. The pooled analysis suggested that the difference between the 2 groups was statistically significant (P<.00001; SMD=2.13; 95% CI [1.71, 2.55]) (Fig. 15).

3.23. MPV

Three trials^[22,23,34] evaluated the effect of MPV increase. There was no significant heterogeneity between the 2 groups (P=.48, $I^2=0\%$), so the fixed-effects model was used. The pooled analysis suggested that the difference between the 2 groups was statistically significant (P<.00001; SMD=2.59; 95% CI [2.14, 3.05]). The effect estimates are shown in Figure 16.



Figure 15. Meta-analysis of the increase of PT in ulcerative colitis. PT= prothrombin time.





3.24. Relapse rate

Nine trials^[22–25,31,34,40,49,57] evaluated the effect of relapse rate. A total of 102 patients relapsed, with a rate of 27/192 in the treatment group and 75/137 in the control group. There was no significant heterogeneity for relapse rate between the 2 groups (P=.99, I^2 =0%). The meta-analysis was performed using a fixed-effects model. The pooled analysis suggested that the difference between the 2 groups was statistically significant (P<.00001), with RR of 0.26 and 95% CI (0.18, 0.38) (Fig. 17).

3.25. Adverse effects

Through a careful reading of the 39 included studies, 14 trials^{[22-} ^{25,27,34–40,56,59]} mentioned the occurrence of adverse effects. Five trials^[23,27,35,38,39] reported that no adverse effects occurred. Nine trials^[22,24,25,34,36,37,40,56,59] reported adverse effects incidence; specifically, 18 out of 453 patients undergoing treatment with KFXL combined with ASA reported adverse events, and 25 out of 459 patients undergoing treatment with ASA showed side effects. The adverse events mainly included nausea, bloating, rash, headache, dizziness, and vomiting. No severe adverse events were reported. The remaining 25 trials^[26,28-33,41-55,57,58,60] did not mention the occurrence of adverse effects. The pooled analysis indicated that there was no obvious difference in the incidence of adverse effects between the 2 groups (P=.31), with RR of 0.74 and 95% CI (0.42, 1.32) (Fig. 18). The results suggested that KFXL combined with ASA might be a safe approach in managing UC.

3.26. Sensitivity analysis

To evaluate the reliability of our meta-analytical data, we tested sensitivity using the 'leave-one-out' approach. Removal of any



Figure 14. Meta-analysis of the reduction of Plt in ulcerative colitis. Plt = platelet.







one study from the analysis of clinical remission rate in UC patients did not significantly affect the outcome. Regardless of the exclusion of individual studies, the consistency in the direction and magnitude of the combined estimates indicated that the meta-analysis had good reliability.

3.27. Publication bias

A forest plot of the comparison of KFXL combined with ASA and ASA alone for the outcome of clinical remission rates is shown in Figure 18. This test found significant evidence of publication bias for clinical remission rates in the studies (Fig. 19).

4. Discussion

4.1. Summary of evidence

This meta-analysis provides a quantitative synthesis of the clinical efficacy of KFXL combined with ASA for the treatment of UC by integrating outcomes from 39 clinical trials involving 3204 participants. In our study, twenty-8 trials are about KFXL combined with 5-ASA vs 5-ASA alone, ten trials are about KFXL combined with SASP vs SASP alone, and one trial is about KFXL combined with OSLS vs OSLS alone. The results from the metaanalysis revealed the following: compared to ASA used alone, KFXL combined with ASA treatment showed a higher clinical remission rate (RR = 1.19) and a lower relapse rate (RR = 0.26); compared with ASA alone, doses of 30 mL (en, qd/qn), 50 mL (en, qd/qn), 50 mL (en, bid), 100 mL (en, qd), and 10 mL (po, tid) of KFXL combined with ASA all significantly improved the clinical remission, with RR = 1.14 (95% CI = 1.07, 1.22, n=6), RR=1.18 (95% CI=1.13, 1.24, n=15), RR=1.17 (95% CI= 1.10, 1.25, n=4), RR=1.24 (95% CI=1.14, 1.34, n=7), and RR = 1.23 (95% CI = 1.10, 1.39, n = 3), respectively; KFXL



combined with ASA could significantly reduce the inflammation factor level of TNF- α , IL-1, IL-6, IL-8, and CRP in patients with UC; KFXL combined with ASA could improve the intestinal mucosa and symptoms in patients with UC; KFXL combined with ASA was superior to the control groups regarding reducing the FIB and Plt values and increasing the PT and MPV values; and compared to the control groups, KFXL combined with ASA showed a lower adverse effects rate, but the difference between the 2 groups was not statistically significant (P=.31). However, the overall estimated results should be interpreted cautiously, considering the high risk of bias.

4.2. Limitations

Certain limitations of our meta-analysis should be described. First, although we have conducted a comprehensive literature search in the 7 electronic databases, databases published in other languages except Chinese and English were not included in our study. All of the 39 included studies were conducted in China and published in Chinese; thus, some relevant publications of KFXL combined with ASA in treating UC might have been missed.

Second, only 14 out of 39 trials mentioned the occurrence of adverse effects. Among these, 5 trials reported that no adverse effects occurred, and 9 trials reported the adverse effects incidence. The rest of the included studies did not mention adverse events at all. So the safety of KFXL combined with ASA in the treatment of UC is limited. More trials are necessary to be conducted to assess the safety of KFXL combined with ASA in treating UC.

Third, we understand that negative results are often difficult to report in China, and all of the included studies reported positive results, so a certain degree of potential selection bias might exist. Previously published systematic reviews of Chinese herbal medicine have confronted similar questions.^[61,62]

Fourth, the methodological quality in the studies was generally poor. All of the eligible articles were nonblinded RCTs. Though randomization was mentioned in all trials, only eleven trials reported the methods of randomization, and no trials reported the blinding of outcome assessment, the loss of cases, or intention analysis. Blinding and allocation concealment were not reported in these RCTs, which meant potential risk of implementation bias. These potential biases were more likely to overestimate the combined effect size. Further well-designed, randomized, doubleblinded, multi-center studies are needed to make a more definite conclusion.

5. Conclusions

In conclusion, KFXL combined with ASA could improve clinical remission, symptoms, intestinal mucosa, inflammation factor level, coagulation index, and relapse rate in UC patients. This systematic review and meta-analysis provides an evidence-based approach to the management of UC. KFXL combined with ASA may be a new treatment for UC. However, some limitations such as potential selection bias and methodological flaws might undermine the validity of positive findings. From a clinical point of view, further RCTs with high-quality and long-term follow-up are recommended to generate a high level of clinical evidence.

Acknowledgments

We thank the National Natural Science Foundation of China and Guangzhou University of Chinese Medicine for their funds.

Author contributions

Data curation: De-tang Li.

Formal analysis: Zhen-wen Qiu.

Methodology: Hong-mei Tang.

- Writing original draft: Hui-biao Li, Mu-yuan Chen.
- Writing review & editing: Qing-qun Cai, Hong-mei Tang, Xin-lin Chen.

References

- Chunjing J, Yuan Z, Yu L. Advances in immunological factors in the pathogenesis of ulcerative colitis. Chin J Cell Mol Immunol 2013;29:889–92.
- [2] Anne W, John M, Kashyap T. Inflammatory bowel disease. Primary Care 2011;38:415–32.
- [3] Baumgart DC, Bernstein CN, Abbas Z, et al. IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010—Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis 2011;17:639–44.
- [4] Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010;16:112.
- [5] Saleh M, Trinchieri G. Innate immune mechanisms of colitis and colitisassociated colorectal cancer. Nat Rev Immunol 2011;11:9.
- [6] Yang W, Wang L, Xiang HY, et al. The immunomodulatory effects of Kangfuxin solution in the mice. West China J Pharm Sci 2011;26:543–6.
- [7] Jiang LY, Liu X, Xia CL, et al. Research advance on chemical constituents and anti-tumor effects of Periplaneta americana L. Med Plant 2012;3:95–7. 102.
- [8] Zheng Z, Chen WX, Chen NW, et al. Study on the mechanisms of Kangfuxin solution in the treatment of acute experimental colitis in rats. Chin J Gastroenterol 2008;13:31–4.
- [9] Zheng M, Qian JM, Li JN, et al. A study on effect and mechanism of Kangfuxinye on oxazolone induced colitis in mice. Chin J Gastroenterol 2012;8:457–61.
- [10] Lu YM, Jin Y, Chen WX, et al. Investigation of the effect of Kangfuxin on experimental col itis in mice. Chin J Clin Med 2011;18:446–9.
- [11] Zhang CL. Study on curative effect and mechanism of Kangfuxin liquid in treatment of ulcerative colitis model in mice. Peking Union Med Coll (PhD Thesis) 2016;65.
- [12] Wang PC, He M, Zhang HC, et al. Effect of Kangfuxin Liquid on 2.4two nitro chlorobenzene combined with acetic acid induced ulcerative colitis in rats. J Dali Univ 2016;1:17–21.
- [13] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;7:264–9.
- [14] National Symposium on Chronic DiseasesDiagnosis and therapeutic criteria of ulcerative colitis. Chin J Gastroenterol 1996;1:110.
- [15] Ouyang Q, Pan GZ, Wen ZH, et al. Recommendations for the diagnosis and treatment of inflammatory bowel disease. Chin J Dig 2001;40:138– 41.
- [16] Xue LY, Ouyang Q. World practice guidelines for IBD recommended by the world gastroenterology organization. Int J Dig Dis 2010;30:195–9.
- [17] Zhang SS. Consensus opinion on TCM diagnosis and treatment of ulcerative colitis. China J Tradit Chin Med Pharm 2010;25:891–5.
- [18] Ouyang Q, Hu PJ, Qian JN, et al. Consensus opinion on the diagnosis and treatment of inflammatory bowel disease in China (2007, Jinan). Chin J Dig 2007;27:545–50.
- [19] Chen ZS, Wei BI, Zhang WD, et al. Combined treatment of traditional Chinese medicine and Western medicine for ulcerative colitis (Draft). Chin J Integr Tradit Western Med 2005;2:133–6.
- [20] Zheng XY. Guidelines for Clinical Research of New Drugs. 2002;China Medical Science Press,
- [21] Shuster JJ. Higgins JPT, Green S. Cochrane handbook for systematic reviews for interventions, Version 5.1.0. Research Synthesis Methods 2011;126–30. 2.
- [22] Huang DX, Lu CQ, He ZP. The influence on coagulation indexes and serum inflammatory cytokines in the treatment of ulcerative colitis in the elderly with Mesalazine and Kangfuxin Liquid. Chin J Gerontol 2013;15:3769–70.
- [23] Tang QF, Zeng W. Effect of Kangfuxin Liquid Combined with Mesalazine on the inflammatory factor and blood clotting function for elderly patients with ulcerative colitis. Mod J Integ Tradit Chin West Med 2016;26:2911–3.

Medicine

- [24] Shi ZJ, Chen XL. The effect of Kangfuxin liquid combined with Mesalazine in the treatment of ulcerative colitis for elderly patients. Clin Res Pract 2016;1:74–5.
- [25] Li Y, Liu Y, Xu YP, et al. The effect of Kangfuxin liquid combined with Mesalazine in the treatment of ulcerative colitis and effect on serum inflammatory cytokines and T lymphocyte subsets level. West China J Pharm Sci 2017;32:111–2.
- [26] Liu YJ, Chen MS, Lu ZY, et al. Effect observation of Kangfuxin solution for retention enema combined with oral administration of mesalazine in the treatment of ulcerative colitis. China Mod Med 2015;22:85–7.
- [27] Pan G, Zhun Z. Kangfuxin retention enema in treatment of ulcerative colitis. Clin Focus 2011;26:1258–9.
- [28] Wang QL. Clinical observation of Kangfuxin enema combined with Mesalazine for treating ulcerative colitis. Shanxi Med J 2014;43:539–40.
- [29] Jin JR, Fan YJ. Clinical study of Kangfuxin liquid combined with Mesalazine in the treatment of ulcerative colitis. Henan Tradit Chin Med 2015;11:2725–7.
- [30] He DL. Curative effect observation of retention enemas with Kangfuxin solution combined mesalazine in patients with distal ulcerative colitis. Clin Med 2015;35:27–9.
- [31] Bai BJ, Huang GM, Zhu LY. The clinical effect of Kangfuxin liquid combined with Mesalazine in the treatment for 68 patients with ulcerative colitis. West China J Pharm Sci 2012;27:728.
- [32] Zhang C. Observation on short-term clinical effect of clysis therapy in ulcerative colitis patients with Kangfuxin solution. Clin Med Eng 2012;19:404–5.
- [33] Zheng LJ, Ma J, Xing JL, et al. The effect of Kangfuxin liquid combined with Mesalazine in the treatment of ulcerative colitis. Chin J Integr Tradit West Med Dig 2015;23:728–30.
- [34] Gong JQ, An CF, Zhang LS. Curative efficacy of mesalazine in combination with Kangfuxin solution enema in treat-ment of ulcerative colitis and its effects on coagulation parameters. Med J Chin PAPF 2015;26:440–3.
- [35] Ouyang YJ, Zhang YM. Mesalazine combined with Kangfuxin Liquid in treatment of ulcerative colitis. Jilin Med J 2011;32:3236–7.
- [36] Ouyang WG, Yan HB. The clinical effect of Mesalazine combined with Kangfuxin Liquid in treatment of ulcerative colitis. Chin J Integr Tradit West Med Dig 2014;22:400–1.
- [37] Li Y, Xie YK, Ding HL, et al. The effect of Mesalazine combined with Kangfuxin Liquid on serum cytokines in the treatment of ulcerative colitis. Shandong Med J 2012;52:55–6.
- [38] Tan Z, Zeng SL, Wang D. Clinical study of Mesalazine combined with Kangfuxin Liquid on ulcerative colitis. Guide China Med 2014;12:262– 3.
- [39] Zeng QG. The clinical effect of Mesalazine combined with Kangfuxin Liquid in the treatment of ulcerative colitis. Chin Foreign Med Res 2013;11:52–3.
- [40] Ma J. The clinical effect of Mesalazine combined with Kangfuxin Liquid in the treatment of ulcerative colitis. Chin J Geriatric Care 2014;12:37–8.
- [41] Fei FM. Clinical observation on ulcerative colitis treated with integrated traditional Chinese and Western Medicine. J N Chin Med 2014;46:81–2.
- [42] Pi J. Mesalazine sustained-release granules combined with Kangfuxin enema in treatment of ulcerative colitis. Med Front 2011;01:102–3.
- [43] Liu HY, Ai YC, Li YL, et al. The clinical observation of Mesalazine combined with Kangfuxin Liquid enema in treatment of ulcerative colitis. Health Horiz Med Sci Fascicule 2014;12:1071–2.
- [44] Gen H, Gu XX, Zhang HB. Clinical observation of Kangfuxin liquid combined with Mesalazine for the treatment of mild to moderate ulcerative colitis. China Health Care Nutr 2016;26:45.
- [45] Zhang D. The curative effect of Mesalazine combined with Kangfuxin solution in treating ulcerative colitis. China Health Care Nutr 2016;26:254.
- [46] Jiao JH. Observation of Kangfuxin Liquid retention enema in the treatment of ulcerative colitis. Med Front 2016;6:148–9.
- [47] Zheng P, Li CH. Clinical Research on Kangfuxin liquid combined with Mesalazin for treating peptic ulcer. Med Inform 2013;6:193–4.
- [48] Xu N. Clinical observation of 40 cases of oral Mesalazine combined with Kangfuxin Liquid in treatment of ulcerative colitis. China Health Care Nutr 2014;24:4235.
- [49] Yin CG. Analysis of effect of Mesalazine combined with Kangfuxin Liquid in treatment of ulcerative colitis. Medical Inform 2014; 27:266.
- [50] Wang L. The curative effect of Kangfuxin retention enema combined with sulfasalazine in treatment of ulcerative colitis. Chin J Ethnomed Ethnopharm 2013;22:60.
- [51] Wang JM, He XH, Li HQ. Kangfuxin retention enema in the treatment of 26 cases of ulcerative colitis. Med J West China 2006;18:629.

- [52] Xu CF. The effect of Kangfuxin retention enema in treatment of ulcerative colitis. J Med Theory Pract 2015;17:2328–9.
- [53] Wu W, Yu FL. Kangfuxin retention enema in treatment of 35 cases of ulcerative colitis. Jiangxi Med J 2009;44:596–7.
- [54] Li CM. The clinical efficacy of Kangfuxin Liquid enema combined with sulfasalazine in treatment of ulcerative colitis. Guide China Med 2014;12:279–80.
- [55] Fan G, Sun Y, Mao C, et al. Clinical observation of Kangfuxin enema combined with sulfasalazine in treatment of ulcerative colitis. Mod J Integr Tradit Chin West Med 2014;23:1436–8.
- [56] Yan AH, Long HH, Liang XL, et al. Clinical study on the treatment of ulcerative colitis with integrated traditional Chinese and western medicine. Hainan Med J 2013;24:2832–4.
- [57] Liu LY. The clinical effect of sulfasalazine enteric tablets combined with Kangfuxin Liquid oral in treatment of ulcerative colitis for children. Med Front 2014;4:69–70.

- [58] Liu J. Analysis of clinical curative effect of Kangfuxin enema combined with sulfasalazine in treatment of ulcerative colitis. Med Front 2013;16:160.
- [59] Gou CH. Clinical study of Kangfuxin Liquid retention enema in treatment of ulcerative colitis. Clin J Chin Med 2010;2:1–2.
- [60] Jin P. Clinical effect of Kangfuxin Liquid combined with olsalazine sodium in the treatment of 80 cases patients with ulcerative colitis. China Health Care Nutr 2013;9:5297.
- [61] Wang PQ, Xiong XJ, Li SJ. Efficacy and safety of a traditional Chinese herbal formula Xuefu Zhuyu decoction for hypertension. Medicine 2015;42:1–8.
- [62] Liu W, Xiong XJ, Yang XC, et al. The effect of Chinese herbal medicine gualouxiebaibanxia decoction for the treatment of angina pectoris: a systematic review. Evid Based Complement Alternat Med 2016;6:1–4.